BIOVIIIx
↗Naples, Italy
BIOVIIIx is an Italian biotechnology company based in Naples, specializing in the development of therapies for hemocoagulopathies and rare diseases, with a particular focus on hemophilia. The company operates as a developer of medical devices and therapeutic solutions, including proprietary technologies for coagulation management.
In recent years, the company has pursued an internationalization strategy, including the acquisition of the German firm Hematris Wound Care in 2023 to expand its portfolio of medical devices. Additionally, the company has engaged in collaborative efforts, such as the merger of its subsidiary Anbition with TagCyx Biotechnologies to form a new entity, Ophyx.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Revenue:$5M-$10M
Founded:2013
Ownership:private
Status:operating
FUNDING
Total Raised:$0M
PIPELINE
Stage:Discovery
Lead Drug Stage:Discovery/Preclinical
Modalities:Medical Devices, Coagulation Factors
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Bioviiix GmbH, Anbition
Key Partnerships:TagCyx Biotechnologies (merger of subsidiary Anbition to form Ophyx)
COMPETITION
Position:Niche Player
Competitors:Kedrion, Octapharma, CSL Behring, Editas Medicine
LEADERSHIP
Key Executives:
Davide Rosiello - CEO
Scientific Founders:Davide Rosiello
LINKS
Website:bioviiix.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of BIOVIIIx and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with BIOVIIIx. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.